开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

未开盘 12-23 16:08:07

1.920

+0.000

0.00%

最高1.950	最低1.890	成交量62.90万
今开1.910	昨收1.920	日振幅3.13%
总市值9.58亿	流通市值9.58亿	总股本4.99亿
成交额120.01万	换手率0.13%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.92,"timestamp":1766477287608,"preClose":1.92,"halted":0,"volume":629000,"delay":0,"floatShares":499000000,"shares":499000000,"eps":-0.39958430827208025,"marketStatus":"未开盘","change":0,"latestTime":"12-23 16:08:07","open":1.91,"high":1.95,"low":1.89,"amount":1200120,"amplitude":0.03125,"askPrice":1.92,"askSize":7500,"bidPrice":1.91,"bidSize":41500,"shortable":0,"etf":0,"ttmEps":-0.4280710252401509,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766539800000},"marketStatusCode":0,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.92,"openAndCloseTimeList":[[1766453400000,1766462400000],[1766466000000,1766476800000]],"volumeRatio":1.4453124997675277,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2593869497","title":"医药巨头年末杀疯了：25亿美元买渐冻症药物，10.6亿美元ADC出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2593869497","media":"MedTrend医趋势","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593869497?lang=zh_cn&edition=full","pubTime":"2025-12-23 19:44","pubTimestamp":1766490240,"startTime":"0","endTime":"0","summary":"盐野义方面表示，预计该交易将于2026年4月1日或之后完成交割，交易完成后每年将为公司新增约7亿美元的全球销售额。根据官方披露，盐野义将以25亿美元的一次性付款方式收购Radicava相关业务，同时约定在“特定条件”下支付潜在的未来特许权使用费。交易交割后，Radicava业务单元将成为盐野义的全资子公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-12-23/doc-inhcuyui5237827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4231","BK1515","BK1574","BK1161","ADC","159938","BK4080","09939"],"gpt_icon":0},{"id":"2593419490","title":"医药创新看中国：“一哥”恒瑞研发瞄定三大策略，构建全球竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2593419490","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593419490?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:15","pubTimestamp":1766481352,"startTime":"0","endTime":"0","summary":"“中国在创新药研发管线方面的规模已占全球的四分之一左右，每年开展的临床试验数量约3000项，这两项关键指标均处于世界前列。”全球医药交易市场也在见证中国力量的崛起。而在创新队列中，恒瑞作为龙头企业，始终占据着重要位置。恒瑞医药董事长孙飘扬在2025年研发日上表示，恒瑞始终坚持创新与国际化战略。这些数据表明中国创新药正从“跟随式创新”迈向“全球领跑”的新阶段。一举创下国内史上BD单笔交易规模最大纪录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223172225a46e4c97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223172225a46e4c97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","BK1161","LU0359202008.SGD","BK1515","09939","LU0359201885.HKD","LU1023057109.AUD","01276","LU0359201612.USD","LU2543165471.USD"],"gpt_icon":0},{"id":"2593499153","title":"每日卖空追踪 | 同源康医药-B 12月23日卖空量成交2500股，卖空比例为0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593499153","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593499153?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:30","pubTimestamp":1766478630,"startTime":"0","endTime":"0","summary":"同源康医药-B北京时间12月23日，跌0.3%，卖空量成交2500股，较上一交易日减少89.13%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163422a6c51e62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163422a6c51e62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","09939","02410","BK1574","BK1161"],"gpt_icon":0},{"id":"2593494070","title":"HTI医药2025年12月第三周周报：行业高景气，持续关注创新药械产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2593494070","media":"海通国际","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593494070?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:07","pubTimestamp":1766477237,"startTime":"0","endTime":"0","summary":"2025年12月第三周A股医药板块表现与大盘相当。2025年12月第三周上证综指上涨0.03%，SW医药生物下跌0.1%，涨跌幅在申万一级行业中排名第19位。截至2025年12月19日，医药板块相对于全部A股的溢价水平目前处于正常水平，当前相对溢价率70.1%。2025年12月第三周美股标普医疗保健精选行业+0.6%，同期标普500+0.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223160731a6c4fe72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223160731a6c4fe72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","06990","HK0000252160.HKD","LU2543165471.USD","09606","BK1161","01530","BK1515","01276","HK0000252152.HKD","HK0000500386.USD","01858","BK1574","02359","02615","01801","02269"],"gpt_icon":0},{"id":"2593741940","title":"12月，石药集团、百济神州、百花村医药等一批药企已“换帅”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593741940","media":"制药网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593741940?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:17","pubTimestamp":1766474250,"startTime":"0","endTime":"0","summary":"如在近期，石药集团、百济神州、百花村医药等一批药企就已纷纷宣布“换帅”。12月19日，石药集团公告宣布执行董事蔡磊接任董事会副主席、首席执行官。12月12日，药明巨诺发布公告，宣布一系列核心管理层及董事会架构调整。除了上述企业，在12月以来，恒瑞医药、康恩贝、南新制药、振东制药等也已发布过高管变动公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223152053a46dc612&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","IE0008369823.USD","LU1951186391.HKD","LU0307460666.USD","IE00BZ08YS42.EUR","LU2543165471.USD","LU1023057109.AUD","IE00B5MMRT66.SGD","09939","LU0588546209.SGD","LU1008478684.HKD","LU1226287529.USD","LU1813983027.USD","LU1960683339.HKD","LU1152091168.USD","BK1161","IE00B543WZ88.USD","01093","LU0880133367.SGD","LU0315179316.USD","BK1191","LU0140636845.USD","LU0501845795.SGD","LU1719994722.HKD","LU2328871848.SGD","LU0326950275.SGD","IE00BZ08YR35.GBP","LU0359202008.SGD","LU1969619763.USD","HK0000165453.HKD","LU1226288170.HKD","BK1583","IE00BZ08YT58.USD","06160","LU1328277881.USD","01276","LU0067412154.USD","LU0314109678.HKD","LU0359201885.HKD","LU0072913022.USD","LU1152091754.HKD","LU1993786604.SGD","BK1500","LU1807302812.USD","LU2039709279.SGD","BK1515","SG9999004220.SGD","LU0359201612.USD","BK1588","IE00B031HY20.USD"],"gpt_icon":0},{"id":"2593462888","title":"鹭燕医药：海南封关将助力医药产品跨境流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2593462888","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593462888?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:07","pubTimestamp":1766473639,"startTime":"0","endTime":"0","summary":"公司于2023年9月对海南鹭燕增资，将海南鹭燕的注册资本由3500万元增至1亿元，用于满足海南鹭燕经营发展及“鹭燕医药海南总部基地项目”建设需要。海南封关，将为公司医药产品跨境流通业务提供助力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300018908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","002788","BK1515","BK1574","BK0250","BK1161"],"gpt_icon":0},{"id":"2593639194","title":"武汉又冲出一个医药IPO！60岁武大学霸带队","url":"https://stock-news.laohu8.com/highlight/detail?id=2593639194","media":"创业邦","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593639194?lang=zh_cn&edition=full","pubTime":"2025-12-23 11:23","pubTimestamp":1766460221,"startTime":"0","endTime":"0","summary":"翰思艾泰正在研发用于癌症及自身免疫疾病精准治疗的创新药，解决该领域未被满足的医疗需求。01湖北农村走出的IPO敲钟人现年60岁的张发明，出生在湖北天门石家河镇的一个普通农村家庭，16岁时考入武汉大学物理化学专业，是家中第一个走出乡村的大学生。以此为平台，张发明正式进军创新药研发。HX009是一款PD-1/SIRPα双功能抗体融合蛋白，其设计旨在同时阻断PD-1免疫抑制信号和CD47-SIRPα介导的免疫逃逸信号，从而协同激活T细胞和巨噬细胞，对抗肿瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223112437a6c409fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223112437a6c409fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1173","BK1515","09939","BK1161","BK1574","03378","BK1535"],"gpt_icon":1},{"id":"2593452284","title":"创金合信医药消费股票A基金经理变动：刘迪不再担任该基金基金经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593452284","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593452284?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:31","pubTimestamp":1766453489,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月23日，创金合信医药消费股票（010585）发布公告，刘迪不再担任该基金基金经理，离任日期为2025年12月23日，变更后创金合信医药消费股票（010585）的基金经理为毛丁丁,皮劲松。截止2025年12月22日，创金合信医药消费股票净值为0.4562，较上一日下跌0.24%，近一年下跌7.78%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300007577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1574","BK1161","BK1515","159938"],"gpt_icon":0},{"id":"2593459642","title":"复星医药拟14.12亿元控股绿谷医药，押注阿尔茨海默病新药后续研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2593459642","media":"中访网数据","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593459642?lang=zh_cn&edition=full","pubTime":"2025-12-23 00:00","pubTimestamp":1766419200,"startTime":"0","endTime":"0","summary":"中访网数据上海复星医药（集团）股份有限公司近日发布公告，回复上海证券交易所关于其对外投资事项的监管工作函。核心信息显示，复星医药拟出资共计14.12亿元，通过受让股权及认购新增注册资本的方式，取得上海绿谷医药有限公司51%的控股权。此次交易的核心标的为绿谷医药旗下已暂停销售的阿尔茨海默病治疗药物甘露特钠胶囊。复星医药表示，此次收购旨在丰富其中枢神经系统疾病治疗领域的产品管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1191","02196","BK1515","BK1593","09939","BK1161"],"gpt_icon":0},{"id":"2593894344","title":"启迪药业最新公告：证券简称拟变更为“古汉医药”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593894344","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593894344?lang=zh_cn&edition=full","pubTime":"2025-12-22 18:49","pubTimestamp":1766400581,"startTime":"0","endTime":"0","summary":"启迪药业(000590.SZ)公告称，公司第十届董事会临时会议于2025年12月22日召开，会议审议通过《关于变更公司证券简称的议案》。公司证券简称将由“启迪药业”变更为“古汉医药”，并向深圳证券交易所提交证券简称变更申请。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200024941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","000590","BK1515","161027","09939","BK0122","BK1161","BK0239","159938"],"gpt_icon":0},{"id":"2593610044","title":"和誉-B(02256)：和誉医药CSF-1R抑制剂贝捷迈®获中国NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593610044","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593610044?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:32","pubTimestamp":1766392338,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，2025年12月22日，公司的附属公司上海和誉生物医药科技有限公司(“和誉医药”)宣布，中国国家药品监督管理局(“NMPA”)批准贝捷迈®(盐酸匹米替尼胶囊)，适用于手术切除可能会导致功能受限或出现较严重并发症的症状性腱鞘巨细胞瘤(“TGCT”)成年患者。获批后，默克将尽快推动该产品惠及中国TGCT患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","BK1574","IE00B5MMRT66.SGD","IE00B543WZ88.USD","159938","09939","CSF","BK1161","02256","LU2488822045.USD","BK1515","LU2476274308.USD","IE00BPRC5H50.USD","LU2476274720.SGD"],"gpt_icon":0},{"id":"2593657109","title":"医药外包概念股逆市受压 康龙化成(03759)跌4.14% 机构指美生物安全法案对华CXO企业经营影响有限","url":"https://stock-news.laohu8.com/highlight/detail?id=2593657109","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593657109?lang=zh_cn&edition=full","pubTime":"2025-12-22 14:06","pubTimestamp":1766383579,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念股逆市受压，截至发稿，康龙化成 跌4.14%，药明生物跌3.75%，药明康德跌2.89%，昭衍新药跌2.67%，泰格医药跌2.07%，金斯瑞生物科技跌1.36%。招银国际表示，MSCI中国医疗指数2025年初至今累计上涨51.9%，跑赢MSCI中国指数24.3%。近期，医药板块有所回调。政策端方面，《生物安全法案》虽已签署生效，但鉴于其未波及Medicaid和Medicare的采购且对关联方定义明确，以及中国CXO美国行政机构收入占比较小，该机构预计该法案对中国CXO企业实质经营影响有限。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972004","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","LU0516422440.USD","09939","BK1576","LU0516423091.SGD","LU0327786744.USD","LU1242518931.SGD","LU0708995583.HKD","BK1574","300759","LU2125910500.SGD","03347","02359","LU0819121731.USD","LU0823426308.USD","LU1720050803.USD","LU2039709279.SGD","LU0417516738.SGD","LU0320764599.SGD","HK0000320223.HKD","HK0000306685.HKD","LU0326950275.SGD","01548","LU0572944931.SGD","BK1141","LU0140636845.USD","HK0000320264.USD","BK1589","BK1610","BK1161","CXO","LU1880383366.USD","LU0359202008.SGD","LU0348735423.USD","LU0051755006.USD","LU1046422090.SGD","HK0000306701.USD","06127","SG9999002463.SGD","BK0216","LU3063872942.SGD","159938","LU0456846285.SGD","03759","02269","LU0359201612.USD","LU0516423174.USD","LU0348825331.USD","SG9999002562.SGD","BK1583"],"gpt_icon":0},{"id":"2593110388","title":"又“急”又“快”，华润系转舵1500亿医药资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2593110388","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593110388?lang=zh_cn&edition=full","pubTime":"2025-12-22 11:41","pubTimestamp":1766374867,"startTime":"0","endTime":"0","summary":"自3月开始，华润系对医药资产的清理从未间断。换言之，今年以来公司的出售又“多”又“急”。截至目前，公司拥有多家上市公司，覆盖A股和港股，合集市值超1500亿元，包括东阿阿胶、江中药业、博雅生物、昆药集团、迪瑞医药等收购标的。截至同期，公司商誉余额242.94亿元，子公司华润三九控股天士力后，商誉增至77.35亿元。此次调整，标志华润系全面主导的开启。江中药业增加2名董事会席位，新提名的白晓松为华润系内部高层。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1766198039497883705","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["09939","BK1574","BK1515","159938","BK1161"],"gpt_icon":0},{"id":"2593177026","title":"劲方医药-B盘中异动 早盘股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593177026","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593177026?lang=zh_cn&edition=full","pubTime":"2025-12-22 10:09","pubTimestamp":1766369371,"startTime":"0","endTime":"0","summary":"2025年12月22日早盘10时09分，劲方医药-B股票出现波动，股价大幅跳水5.10%。截至发稿，该股报25.700港元/股，成交量11.96万股，换手率0.04%，振幅5.47%。劲方医药-B股票所在的药品行业中，整体涨幅为0.14%。其相关个股中，三爱健康集团、泰德医药、雅各臣科研制药涨幅较大，振幅较大的相关个股有君圣泰医药-B、九源基因、劲方医药-B，振幅分别为15.65%、5.82%、5.10%。该公司主要在中国国内和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222100931a4683b70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222100931a4683b70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","BK1515","BK1574","02595"],"gpt_icon":0},{"id":"2593179273","title":"天士力医药拟取消监事会并修订公司章程，预计2026年日常关联交易超16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593179273","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593179273?lang=zh_cn&edition=full","pubTime":"2025-12-22 08:06","pubTimestamp":1766361984,"startTime":"0","endTime":"0","summary":"中访网数据  天士力医药集团股份有限公司于2025年12月26日召开临时股东会，审议多项重要议案。核心内容包括：拟取消监事会设置，由董事会审计委员会行使监事会职权，并对《公司章程》及相关治理制度进行修订，以符合新《公司法》要求。同时，公司预计2026年度将与关联方发生日常经营性关联交易，其中与华润集团及其下属公司预计交易金额约16.23亿元，与天士力生物医药产业集团及其一致行动人预计交易金额约2.31亿元。此外，公司拟变更会计师事务所，由天健会计师事务所变更为毕马威华振会计师事务所，2025年度审计费用为375万元。上述事项均需提交本次股东会审议批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251222/31879893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0183","BK0239","09939","BK0012","159938","BK0196","BK0028","BK1515","BK1574","600535","BK0188","BK1161"],"gpt_icon":0},{"id":"2593489557","title":"医药生物行业动态研究：CRO需求回暖 实验猴供给紧张涨价","url":"https://stock-news.laohu8.com/highlight/detail?id=2593489557","media":"国海证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593489557?lang=zh_cn&edition=full","pubTime":"2025-12-22 00:00","pubTimestamp":1766332800,"startTime":"0","endTime":"0","summary":"临床前CRO 客户需求回暖，上游实验猴供给端紧张。本周沪深300 下跌0.28%，医药生物下跌0.14%，处于31 个一级子行业第22 位，医药子板块中，医药商业板块本周涨幅较大，化学制药、生物制品、医疗器械、医药商业、中药、医疗服务本周涨跌幅分别为-1.74%、-0.67%、1.16%、4.94%、0.17%、0.55%。综合考虑上述因素，我们维持医药生物行业“中性”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222162130a6c08b1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222162130a6c08b1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02359","BK1576","BK1141","LU0320764599.SGD","LU2125910500.SGD","LU2045819591.USD","BK1161","LU0052750758.USD","BK1574","09939","BK1583","LU0708995583.HKD","LU1046422090.SGD","LU2242644610.SGD","BK1515"],"gpt_icon":0},{"id":"2593107812","title":"CTLA4专题：技术革新来临 聚焦“增效减毒”的新一代疗法投资机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2593107812","media":"中泰证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593107812?lang=zh_cn&edition=full","pubTime":"2025-12-22 00:00","pubTimestamp":1766332800,"startTime":"0","endTime":"0","summary":"新版“医保+商保”双目录已于近期发布并将在2026 年1 月1 日正式实施。多特异性抗体与ADC，这是当前创新药研发最火热的领域之一。CTLA-4 专题：CTLA-4 赛道迎来技术革新，聚焦“增效减毒”的新一代疗法投资机遇。新一代CTLA-4 药物通过技术创新，正在解决该靶点商业化最大的障碍——毒性问题，从而有望释放其市场潜力。PD-1/PD-L1 抑制剂已成为多种癌症的一线标准疗法，但耐药性是随之而来的临床难题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222143131a6c01da6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222143131a6c01da6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1961090484.USD","BK1574","IE00B543WZ88.USD","LU0634319403.HKD","BK1515","LU0540923850.HKD","LU0348827113.USD","LU0348783233.USD","02616","LU0348767384.USD","LU0348825331.USD","LU0417516902.SGD","LU0417516738.SGD","LU2488822045.USD","LU0561508036.HKD","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2399975544.HKD","LU0417516571.SGD","LU0348784397.USD","LU2476274308.USD","LU2476274720.SGD","LU0348766576.USD","BK1161","LU2778985437.USD","ADAG","09939","IE00BPRC5H50.USD","09926","LU0348735423.USD","LU1720050803.USD"],"gpt_icon":0},{"id":"2592546146","title":"900亿医药巨头 创二代接任首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=2592546146","media":"中国基金报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592546146?lang=zh_cn&edition=full","pubTime":"2025-12-20 22:02","pubTimestamp":1766239372,"startTime":"0","endTime":"0","summary":"【导读】石药集团董事会主席蔡东晨之子蔡磊接任公司首席执行官在旗下A股上市公司新诺威（石药创新）向港交所递交招股书后不久，石药集团宣布，董事会主席蔡东晨之子、执行董事蔡鑫之兄蔡磊，接任公司董事会副主席、CEO（首席执行官）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512203597499846.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512203597499846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1515","09939","BK1161","159938"],"gpt_icon":0},{"id":"2592711132","title":"商务部发布2026年甘草及甘草制品出口配额公开招标投标企业名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2592711132","media":"北京日报客户端","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592711132?lang=zh_cn&edition=full","pubTime":"2025-12-19 11:45","pubTimestamp":1766115900,"startTime":"0","endTime":"0","summary":"转自：北京日报客户端根据商务部2025年第78号公告，经审核，现将2026年甘草及甘草制品出口配额公开招标投标企业名单发布如下：一、符合鲜或干的甘草投标资格的企业（76家）1.亳州市中药饮片厂2.安徽贺林中药饮片科技有限公司3.安徽和济堂中药饮片有限公司4.安徽谓博中药股份有限公司5.安徽省本草国药饮片有限公司6.安徽盛林国药饮片有限公司7.亳州市盛林中药饮片有限公司8.安徽省天和中药材开发有限公","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-19/doc-inhcicep7777788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1191","BK1515","09939","01477","BK1161"],"gpt_icon":0},{"id":"2592345351","title":"医药股今早显著反弹 凯莱英及药明生物均涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592345351","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592345351?lang=zh_cn&edition=full","pubTime":"2025-12-19 11:05","pubTimestamp":1766113500,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　医药股今早明显反弹，CRO、创新药方向居前。截至发稿，凯莱英（06821）上涨6.07%，报76.85港元；药明生物（02269）上涨6.05%，报34.70港元；三生制药（01530）上涨4.65%，报26.58港元；诺诚健华（09969）上涨4.70%，报13.80港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-12-19/doc-inhcicep7752391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06821","LU0516423174.USD","LU0417516902.SGD","LU0051755006.USD","LU1328615791.USD","LU3063872942.SGD","BK0239","LU0359202008.SGD","LU0456846285.SGD","LU0417516738.SGD","SG9999002463.SGD","159938","IE00B0JY6N72.USD","LU0039217434.USD","LU0043850808.USD","LU0327786744.USD","002821","BK1574","02269","LU0588546209.SGD","LU1688375341.USD","LU0516422366.SGD","LU0320764599.SGD","LU0572944931.SGD","LU1720050803.USD","BK1161","BK1521","LU1794554557.SGD","SG9999002562.SGD","LU0856984785.SGD","LU0516423091.SGD","BK1576","LU0516422952.EUR","LU0823426480.USD","LU0819121731.USD","BK1515","LU0348735423.USD","BK1610","LU0823426308.USD","LU0140636845.USD","LU0979878070.USD","LU0181495838.USD","LU0456827905.SGD","LU1242518857.USD","09939","BK1141","LU0708995583.HKD","LU0052750758.USD","LU0359201612.USD","BK1589"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":-0.0204},{"period":"3month","weight":-0.2351},{"period":"6month","weight":0.28},{"period":"1year","weight":0.9592},{"period":"ytd","weight":0.9794}],"compareEarnings":[{"period":"1week","weight":0.0213},{"period":"1month","weight":0.022},{"period":"3month","weight":-0.0281},{"period":"6month","weight":0.0596},{"period":"1year","weight":0.2963},{"period":"ytd","weight":0.2849}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.063412},{"month":2,"riseRate":0.8,"avgChangeRate":0.219909},{"month":3,"riseRate":0.4,"avgChangeRate":0.084454},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.189069}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}